View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • Herman Caspersen
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Stian Wibstad
 PRESS RELEASE

Coloplast A/S - Opdateret finanskalender 2025-26

Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf.  Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...

 PRESS RELEASE

Coloplast A/S - Updated Financial Calendar 2025-26

Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026.  The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit:   Kind...

ABGSC Construct. & Real Estate Research ... (+4)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Julia Sundvall
  • Oscar Lindquist
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Russell Waller
  • Russell Waller

Telenor (Neutral, TP: NOK 160, -7%) post Q4 25 model update – Impressi...

In this note, we update our model and thoughts following the Q4 results incorporating conference call feedback and compare our new estimates to guidance and consensus.

Telenor ASA: 2 directors

Two Directors at Telenor ASA bought 15,500 shares at between 172.000NOK and 173.500NOK. The significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...

Russell Waller
  • Russell Waller

Telenor (Neutral, TP: NOK 150, -7%) Q4 25: Good results, new Buyback ...

Telenor has reported a good set of Q4 numbers, issued solid guidance for FY26, and announced a new 7% (over 3 years) buyback, that should help it shrug off the recent negative Telia-ICE RAN sharing news (HERE). We downgraded to Neutral in July (HERE) due to insufficient upside to be Buy, and because we saw better value elsewhere in the sector, and we were worried about dividend cover given rising Asian costs. Selling out of Thailand (HERE) helps repair the B/S and supports sentiment. As things s...

Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Telecom Operators Research ... (+3)
  • ABGSC Telecom Operators Research
  • Åsne Holsen
  • Øystein Elton Lodgaard
 PRESS RELEASE

Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26

Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26   2025/26 Delårsrapport, 1. kvartal 2025/261. oktober 2025 - 31. december 2026 Coloplast leverede i 1. kvartal en organisk vækst på 6% og en EBIT vækst1 i faste valutakurser på 3%. Den rapportede omsætning i danske kroner steg 0%, hvilket afspejler en negativ valutaeffekt på 4 procentpoint. Afkast af investeret kapital2 var på 15%. • Organisk vækst pr. område: Stomi 4 %, Kontinens 7 %, Stemme og Respiratorisk Pleje 8 %, Wound & Tissue Repair 5 % og Urologi 8 %.• Svag start i Stomi, som forventet, drevet af negativ vækst i Kina og høj baseli...

 PRESS RELEASE

Coloplast A/S - Interim Financial Report, Q1 2025/26

Coloplast A/S - Interim Financial Report, Q1 2025/26 2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested capital2 was 15%. • Organic growth rates by business area: Ostomy Care 4%, Continence Care 7%, Voice & Respiratory Care 8%, Wound & Tissue Repair 5%, and Interventional Urology 8% .• Soft start in Ostomy Care, as expected, driven by negative growth in China and a high...

 PRESS RELEASE

Telenor reports strong results and announces NOK 15 billion share buyb...

Telenor reports strong results and announces NOK 15 billion share buyback programme Telenor enters 2026 with strong Nordic growth, a solid financial position, and a simplified portfolio in line with the ambitions presented at the Capital Markets Day. “The results for 2025 show that we are delivering on our promises. We are entering 2026 with a simplified portfolio and strengthened financial capacity. I am very proud of the strong efforts of our employees throughout the year, how we continue to put our customers first every day and develop services that provide greater security and add valu...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch